5-HT2c agonist, lorcaserin, reduces aggressive responding in intermittent explosive disorder: A pilot study.

Published in: Human psychopharmacology (2019)

Lorcaserin may possess anti-aggressive properties that could prove useful in the treatment of impulsive aggressive behavior in human subjects. These data, thus, provide a rationale for a follow-up randomized clinical trial of lorcaserin in individuals with prominent histories of impulsive aggressive behavior.

Keyphrases

endothelial cells
high intensity
big data
machine learning
artificial intelligence
double blind
smoking cessation
data analysis